Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,476 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care oral care Clear all
Terminated Phase 3 Interventional Results available

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

NCT03839940
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Dexamethasone, Placebo, Questionnaire, Quality-of-Life Assessment, Everolimus
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
319
States / cities
Birmingham, Alabama • Kingman, Arizona • Fort Smith, Arkansas + 198 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT02352948
View directory record Official record
Conditions
Non - Small Cell Lung Cancer NSCLC
Interventions
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
33
States / cities
Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

NCT05240898
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
RO7623066, Olaparib, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

NCT06265532
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg
Drug
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 3, 2026, 5:39 PM EDT
Withdrawn Phase 2 Interventional

Baricitinib for Cutaneous Dermatomyositis

NCT05361109
View directory record Official record
Conditions
Dermatomyositis
Interventions
Baricitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Study of GS-3242 in Participants With HIV-1; Substudy-05

NCT07001319
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

NCT02967172
View directory record Official record
Conditions
Pain, Postoperative, Ankle Fractures
Interventions
Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 3, 2026, 5:39 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Upper Airway Ultrasound to Predict Difficult Laryngoscopy in Neonates and Infants

NCT07444528
View directory record Official record
Conditions
Neonates, Infants Aged 0 Days to 12 Months Scheduled for Elective Surgery
Interventions
Upper airway ultrasound
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 365 Days
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 3, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

NCT03201445
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Filgotinib, Placebo, Standard of Care
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Group B Streptococcus Response After Probiotic Exposure

NCT04721912
View directory record Official record
Conditions
Group B Strep Infection
Interventions
Probiotic dietary supplement
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional

Losartan for Sickle Cell Kidney Disease

NCT01989078
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Losartan
Drug
Lead sponsor
Emory University
Other
Eligibility
9 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 3, 2026, 5:39 PM EDT
Terminated Phase 4 Interventional Results available

Steroid Use in Non-RSV Bronchiolitis

NCT04221087
View directory record Official record
Conditions
Bronchiolitis, Viral
Interventions
Placebos, Dexamethasone Oral
Drug
Lead sponsor
Allison Williams
Other
Eligibility
1 Day to 2 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 3, 2026, 5:39 PM EDT
Recruiting Phase 2Phase 3 Interventional

Minocycline in Stroke Study at Maimonides

NCT07237048
View directory record Official record
Conditions
Stroke, Ischemia Stroke, Hemorrhagic Strokes, Mortality, Morbidity, Cerebrovascular Accident (Stroke), Intracerebral Haemorrhage (ICH)
Interventions
Minocycline 200mg
Drug
Lead sponsor
Joyce Chen
Other
Eligibility
18 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

NCT05901831
View directory record Official record
Conditions
Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions
Finerenone, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
28
States / cities
Surprise, Arizona • Stanford, California • Vallejo, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

NCT02480114
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions
Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 3, 2026, 5:39 PM EDT
Terminated Phase 4 Interventional Results available

Aspirin and Enoxaparin for VTE in Trauma

NCT02396732
View directory record Official record
Conditions
Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions
Aspirin, Enoxaparin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT04054193
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 3, 2026, 5:39 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299
View directory record Official record
Conditions
HIV-1-Infection
Interventions
ISL/LEN, Antiretroviral Combinations
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Gut Liver Axis in Cirrhosis

NCT03030820
View directory record Official record
Conditions
Cirrhosis, Periodontitis, Gingivitis
Interventions
Dental Cleaning
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Study in Adults With Type 2 Diabetes

NCT01421459
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, Lantus, OAMs
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

NCT03037437
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib (SOR), Hydroxychloroquine (HCQ)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 100 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 3, 2026, 5:39 PM EDT